IL-12

BIOLOGICAL6 trials

Sponsors

Dana-Farber Cancer Institute, National Institute of Allergy and Infectious Diseases (NIAID), University Health Network, Toronto, Specialty Networks Research.

Conditions

Acute Myeloid LeukemiaCrohn Disease (CD)CryptosporidiosisHIV InfectionsHead and Neck CancerUlcerative Colitis (UC)

Phase 1

Interleukin 12 (IL-12) for the Treatment of Cryptosporidiosis in AIDS Patients

TerminatedNCT00057486

National Institute of Allergy and Infectious Diseases (NIAID)Cryptosporidiosis, HIV Infections

Start: 1997-09-30End: 2005-06-30Target: 2Updated: 2016-12-14

Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer

CompletedNCT00004070

Dana-Farber Cancer InstituteHead and Neck Cancer

Start: 1999-07-31End: 2000-12-31Updated: 2017-04-20

Safety and Effectiveness of PENNVAX-B Vaccine Alone, With Il-12, or IL-15 in Healthy Adults

CompletedNCT00528489

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2007-10-31End: 2010-01-31Updated: 2021-10-14

Safety of and Immune Response to an Investigational HIV-1 Vaccine With or Without Interleukin-12 (IL-12) in HIV-1 Infected Adults

CompletedNCT01266616

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2011-03-31End: 2013-04-30Updated: 2021-11-01

A Study of (Interleukin-12) IL-12 in Patients With Acute Myelogenous Leukemia (AML)

Active, not recruitingNCT02483312

University Health Network, TorontoAcute Myeloid Leukemia

Start: 2015-09-30End: 2026-08-31Target: 9Updated: 2025-12-01

Phase 4

INSIGHT-IBD Pragmatic Study

Not yet recruitingNCT07686757

Specialty Networks Research.Crohn Disease (CD), Ulcerative Colitis (UC)

Start: 2026-06-01End: 2028-06-01Target: 400Updated: 2026-07-07